Samsung Medical Center

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: Subsidiary

Established: 1994-01-01

Employees: 501

Market Cap: -

Website: http://www.samsunghospital.com

Clinical Trials

Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors

Not Applicable

Withdrawn

Conditions: Refractory Solid Tumors

Interventions: Drug: Sorafenib

First Posted Date: 2016-02-25

Last Posted Date: 2019-12-30

Lead Sponsor: Samsung Medical Center

Registration Number: NCT02691780

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors

Phase 4

Completed

Conditions: Refractory Solid Tumors

Interventions: Drug: Sunitinib

First Posted Date: 2016-02-25

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 1

Registration Number: NCT02691793

Locations: 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of

Intercontinental Cooperative Non-Hodgkin T-cell Lymphoma Prospective Registry Study

Completed

Conditions: Non-Hodgkin T-cell Lymphoma

Interventions: Other: Prospective Registry

First Posted Date: 2016-02-25

Last Posted Date: 2020-09-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 500

Registration Number: NCT02691351

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Development of Skin Adhesive Patches for the Monitoring and Prediction of Mental Disorders

Not Applicable

Conditions: Major Depressive Disorder, Anxiety Disorder

Interventions: Behavioral: cognitive stress (serial 7)

First Posted Date: 2016-02-24

Last Posted Date: 2016-02-24

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 80

Registration Number: NCT02690324

Locations: 🇰🇷
Samsung Medical Center, Seoul, Irwon-dong, Gangnam-gu, Korea, Republic of

A Study on the Changes of the Biological Rhythm by Display Image Modulation

Not Applicable

Completed

Conditions: Circadian Rhythm Phase Shift

Interventions: Device: smartphone display

First Posted Date: 2016-02-24

Last Posted Date: 2016-02-24

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 22

Registration Number: NCT02690311

Phase II, Single-arm Study of AZD1775 Monotherapy in Relapsed Small Cell Lung Cancer Patients With MYC Family Amplification or CDKN2A Mutation Combined With TP53 Mutation

Phase 2

Terminated

Conditions: Small Cell Lung Cancer

Interventions: Drug: AZD1775

First Posted Date: 2016-02-23

Last Posted Date: 2018-09-20

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 7

Registration Number: NCT02688907

Locations: 🇰🇷
Keunchil Park, Seoul, Korea, Republic of

Study to Evaluate the Safety and Efficacy of Sirolimus, in Subject With Refractory Solid Tumors

Phase 4

Completed

Conditions: Refractory Solid Tumors

Interventions: Drug: sirolimus

First Posted Date: 2016-02-23

Last Posted Date: 2022-06-15

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 6

Registration Number: NCT02688881

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]

Recruiting

Conditions: Neuroendocrine Carcinoma
Small Cell Lung Cancers

Interventions: Other: No treatment is included in this protocol.

First Posted Date: 2016-02-23

Last Posted Date: 2024-01-03

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 797

Registration Number: NCT02688894

Locations: 🇰🇷
Ulsan University Hospital, Ulsan, Korea, Republic of
🇰🇷
Chungbuk University Hospital, Chungbuk, Korea, Republic of
🇰🇷
Gachon University Gil Medical Center, Incheon, Korea, Republic of

and more 3 locations

The Lamina Cribrosa (LC) Changes in the Eyes After Laser-Assisted in Situ Keratomileusis (LASIK)

Completed

Conditions: The Lamina Cribrosa and Optic Nerve Head Changes

Interventions: Device: Exposed to the high pressure during the surgery

First Posted Date: 2016-02-08

Last Posted Date: 2016-02-08

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 40

Registration Number: NCT02676557

Follow-Up Study of Safety of Pneumostem® in Premature Infants With Intraventricular Hemorrhage

Conditions: Intracranial Hemorrhages
Mesenchymal Stem Cells
Newborn Infant

First Posted Date: 2016-02-04

Last Posted Date: 2019-04-09

Lead Sponsor: Samsung Medical Center

Target Recruit Count: 9

Registration Number: NCT02673788

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy